Kura Oncology said its board compensation committee granted inducement awards to four new employees consisting of nonstatutory stock options to buy a total of 44,700 common shares under its amended 2023 Inducement Option Plan. The options carry an exercise price of $8.68 per share and vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, subject to continued service.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603060730PRIMZONEFULLFEED9666924) on March 06, 2026, and is solely responsible for the information contained therein.